BioMarin Pharmaceutical Inc. Stock Was Bought By Options Traders

 BioMarin Pharmaceutical Inc. Stock Was Bought By Options Traders

In today’s session BioMarin Pharmaceutical Inc. (BMRN) registered an unusually high (504) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious BMRN increase. With 504 contracts traded and 2014 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: BMRN161216C00090000 closed last at: $2.35 or 51.6% up. About 392,925 shares traded hands. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 1.23% since April 5, 2016 and is downtrending. It has underperformed by 3.18% the S&P500.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Out of 16 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 12 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 75% are positive. $175 is the highest target while $99 is the lowest. The $129.27 average target is 55.07% above today’s ($83.36) stock price. BioMarin Pharmaceutical has been the topic of 36 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was maintained by Wedbush with “Neutral” on Tuesday, August 25. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Outperform”. Oppenheimer maintained the shares of BMRN in a report on Wednesday, November 25 with “Perform” rating. The rating was maintained by Jefferies with “Buy” on Tuesday, August 25. The company was maintained on Monday, October 5 by Wedbush. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Neutral” rating by Wedbush on Tuesday, January 19. As per Friday, August 5, the company rating was maintained by Piper Jaffray. The stock has “Conviction Buy” rating given by Goldman Sachs on Monday, March 7. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. The firm has “Neutral” rating by Wedbush given on Tuesday, September 1.

According to Zacks Investment Research, “BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin’s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.”

Insitutional Activity: The institutional sentiment increased to 1.28 in 2016 Q2. Its up 0.10, from 1.18 in 2016Q1. The ratio increased, as 34 funds sold all BioMarin Pharmaceutical Inc. shares owned while 104 reduced positions. 37 funds bought stakes while 140 increased positions. They now own 153.99 million shares or 5.12% less from 162.30 million shares in 2016Q1.
Blue Jay Capital Mngmt Limited Co accumulated 152,253 shares or 7.78% of the stock. Dai Ichi Life Insurance Ltd holds 0.04% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 17,457 shares. American Natl Registered Investment Advisor last reported 0.16% of its portfolio in the stock. Allianz Asset Management Ag has 0.03% invested in the company for 668,746 shares. Principal Fincl Grp Inc last reported 0% of its portfolio in the stock. Rhenman & Prtn Asset Management holds 2.07% or 150,000 shares in its portfolio. Columbus Circle Invsts owns 178,355 shares or 0.14% of their US portfolio. Brown Advisory has invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Bancorpsouth accumulated 0.02% or 2,697 shares. Cornerstone Advsr holds 0.08% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 950 shares. The United Kingdom-based Marshall Wace Ltd Liability Partnership has invested 0.05% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Tekla Ltd has 2.08% invested in the company for 653,845 shares. Shell Asset Mngmt has 27,415 shares for 0.05% of their US portfolio. Fortaleza Asset Incorporated has invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Kopp Limited Liability Company accumulated 0.48% or 11,697 shares.

Insider Transactions: Since May 18, 2016, the stock had 0 insider buys, and 21 insider sales for $58.33 million net activity. FUCHS HENRY J sold $1.32 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, May 26. Mueller Brian also sold $28,700 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. 64,125 shares with value of $5.58 million were sold by BIENAIME JEAN JACQUES on Wednesday, August 3. Shares for $195,030 were sold by Davis George Eric. Shares for $146,992 were sold by SPIEGELMAN DANIEL K. On Friday, July 22 the insider LAWLIS V BRYAN sold $608,064. BAFFI ROBERT sold $435,249 worth of stock.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for various diseases and medical conditions. The company has a market cap of $14.61 billion. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. It currently has negative earnings. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

BMRN Company Profile

BioMarin Pharmaceutical Inc. (BioMarin), incorporated on October 25, 1996, develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and in other countries. Naglazyme received marketing approval in the United States, the European Union and in other countries. Kuvan was granted marketing approval in the United States and the European Union. Aldurazyme was approved for marketing in the United States, the European Union and in other countries. Firdapse received marketing approval in the European Union.

More news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were recently published by: Schaeffersresearch.com, which released: “Analyst Update: Acacia Communications, Inc., BioMarin Pharmaceutical Inc., and …” on November 07, 2016. Gurufocus.com‘s article titled: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million …” and published on November 01, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Related posts

Leave a Comment